AstraZeneca’s Once-Daily SEROQUEL XR Extended-Release Tablets Approved In Netherlands For The Acute And Long Term Treatment Of Schizophrenia
AstraZeneca announced the Netherlands regulatory authority MEB (Medicines Evaluation Board) has approved SEROQUEL XR? (quetiapine fumarate) Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in adult patients. With SEROQUEL XR? patients can achieve a dose within the recommended range as early as the second day of treatment and the MEB approval also includes relapse prevention in the long-term treatment of schizophrenia.
